Evidence map›Paper›PMID 37652493›Full record

Trial reportIn vivo (Athens, Greece)

A Prospective Study of AFree Oral Spray as an Adjuvant Therapy for Mild and Moderate COVID-19 in Community Health Stations: Clinical Progression and Viral Clearance Outcomes.

Duong T Tran, Truong N Pham, Nhung Ht Nguyen, Hau D Tran, Huy Q Hoang, B O Han, Ba X Hoang

Open access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Duong T Tran19-8 Hospital, Ministry of Public Security, Hanoi, Vietnam.
Truong N Pham19-8 Hospital, Ministry of Public Security, Hanoi, Vietnam.
Nhung Ht NguyenUniversity of Medical Technology, Department of Clinical Laboratory, Hai Duong, Vietnam.
Hau D TranNational Children Hospital, Department of Oncology, Hanoi, Vietnam.
Huy Q HoangNatural Health Medical Center, Lawndale, CA, U.S.A.
B O HanNimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.A.
Ba X HoangNimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.A. baxuanho@usc.edu.
University of Southern California · USAmerican Museum of Natural History · USUniversity of Hai Duong · VNVietnam National Children's Hospital · VNVietnam National University, Hanoi · VNViet Nam University Of Traditional Medicine · VN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe aim of this study was to evaluate the safety and efficacy of AFree oral spray, in combination with Standard of Care, in treating mild to moderate COVID-19 patients. This was an open-label, single-blinded, and controlled randomized clinical trial. PATIENTS AND

methodsThe study involved 1,252 patients, who were randomly assigned to either the control or study group, with 626 patients in each group. Patients in the control group were treated with Standard of Care recommended by the Ministry of Health of Vietnam, while patients in the study group received AFree oral spray in addition to Standard of Care for a period of 10 days. The clinical progression and outcomes of both groups were compared.

resultsThe results showed that the proportion of patients with clinical symptoms on the 5

conclusionThe use of AFree oral spray resulted in significant improvements in clinical symptoms, recovery time, and viral clearance in COVID-19 patients with mild to moderate symptoms. This therapy has been shown to be safe and can be used as an adjuvant treatment for COVID-19 as well as other respiratory viral infections.

Indexed as

COVID-19Disease ProgressionHumansOral SpraysProspective StudiesPublic HealthSARS-CoV-2Treatment OutcomeOral SpraysAFreeCOVID-19dimethyl sulfoxideDMSOIodideSARS-COV-2viral infectionZinc

Identifiers

PMID37652493
PMCPMC10500509
OpenAlexW4386311070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.